HELPING THE OTHERS REALIZE THE ADVANTAGES OF MBL77

Unfit sufferers also have the choice of venetoclax additionally obinutuzumab (VO) as frontline therapy. This is based on the phase III demo that when compared VO with ClbO in elderly/unfit patients.113 VO was exceptional regarding response rate and development-cost-free survival, and had a similar security profile. In this trial VO was administered